Alkermes plc ALKS

NAS: ALKS | ISIN: IE00B56GVS15 2/07/2025

29,00 USD (+0,05%)

(+0,05%) 2/07/2025

Grafiek Alkermes plc

Grafiek Alkermes plc

1 dag1d 0,05%
1 week1w 0,66%
1 maand1m -8,05%
3 maanden3m -3,53%
6 maanden6m 1,86%
1 jaar1j 19,39%
5 jaar5j 47,73%

Alkermes plc in het nieuws

Toon enkel gratis nieuws

1 mei 2025 · Alkermes plc Reports First Quarter 2025 Financial Results · Persbericht

30 april 2025 · New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD) · Persbericht

17 april 2025 · Alkermes to Report First Quarter Financial Results on May 1, 2025 · Persbericht

2 april 2025 · Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference · Persbericht

1 april 2025 · Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia · Persbericht

27 maart 2025 · New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder · Persbericht

13 september 2024 · Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program · Persbericht

28 augustus 2024 · Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference · Persbericht

22 augustus 2024 · Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2 · Persbericht

24 juli 2024 · Alkermes plc Reports Second Quarter 2024 Financial Results · Persbericht

Profiel Alkermes plc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

CEO: Richard F. Pops

Werknemers: 2.482

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe